This Bill Replaced with a Substitute Bill - Check Primary Bill - HB 2817 - 02/26/2026 - HCS Reported Do Pass (H)
Email me when HB 2961 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HB 2961. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill creates a program that funds and monitors clinical drug trials of ibogaine for opioid use disorder and other neurological conditions, requiring matching private funds and collaboration with out‑of‑state consortia. It also restricts ibogaine prescribing to doctors licensed under chapter 334 who must administer the drug in a hospital or other licensed health‑care facility. The goal is to develop new treatment options for veterans and other at‑risk Missourians.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HB 2961
3 free questions a day, no accountVote
8 yes
1 no
2 other
HCS Reported Do Pass (H) - AYES: 8 NOES: 1 PRESENT: 2 · Feb 26, 2026
History
- HCS Reported Do Pass (H) - AYES: 8 NOES: 1 PRESENT: 2
- HCS Voted Do Pass (H)
- Executive Session Completed (H)
- Public Hearing Completed (H)
- Referred: Emerging Issues(H)
- Read Second Time (H)
- Introduced and Read First Time (H)
Sponsors
- Richard West (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HB 2961 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HB 2961 freeOr ask your AI assistant about HB 2961 directly:
Add to Claude, ChatGPT or Cursor